Rubius Therapeutics (Rubius Therapeutics) Debt-to-Equity : 0.07 (As of Dec. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Rubius Therapeutics Debt-to-Equity?

Rubius Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $1.10 Mil. Rubius Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. Rubius Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $15.13 Mil. Rubius Therapeutics's debt to equity for the quarter that ended in Dec. 2022 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Rubius Therapeutics's Debt-to-Equity or its related term are showing as below:

RUBY's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Rubius Therapeutics Debt-to-Equity Historical Data

The historical data trend for Rubius Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rubius Therapeutics Debt-to-Equity Chart

Rubius Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.18

0.35

0.82

0.64

0.07

Rubius Therapeutics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-Equity	Get a 7-Day Free Trial															0.64	0.84	1.17	3.03	0.07

Competitive Comparison of Rubius Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Rubius Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rubius Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rubius Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Rubius Therapeutics's Debt-to-Equity falls into.

Rubius Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Rubius Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.1	+	0)	/	15.131
	=	0.07

Rubius Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.1	+	0)	/	15.131
	=	0.07

Rubius Therapeutics (OTCPK:RUBY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Rubius Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Rubius Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rubius Therapeutics (Rubius Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rubius Therapeutics Inc (OTCPK:RUBY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

124 Washington Street, Suite 101, Foxborough, MA, USA, 02035

Website

https://www.rubiustx.com

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

Executives

Dannielle Appelhans	officer: CEO and President	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Pablo J Cagnoni	director, officer: Chief Executive Officer	ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Laurence A. Turka	officer: Chief Scientific Officer	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE MA 02139
Susanne Schaffert	director	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
David R Epstein	director	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Maiken Keson-brookes	officer: CLO & Corp. Secretary	35 OAK HILL ROAD, FAYVILLE MA 01745
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Jose Carmona	officer: Chief Financial Officer	C/O INNOCOLL HOLDINGS PLC, 3803 WEST CHESTER PIKE, NEWTOWN SQUARE PA 19073
Christina M. Coughlin	officer: Chief Medical Officer	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE MA 02139